Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 18,800 Shares of Boston Scientific Co. (NYSE:BSX)

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its position in Boston Scientific Co. (NYSE:BSX) by 6.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 255,558 shares of the medical equipment provider’s stock after selling 18,800 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Boston Scientific were worth $22,826,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. Private Advisor Group LLC raised its stake in Boston Scientific by 2.7% in the 3rd quarter. Private Advisor Group LLC now owns 36,003 shares of the medical equipment provider’s stock valued at $3,017,000 after acquiring an additional 944 shares during the period. DT Investment Partners LLC grew its holdings in Boston Scientific by 65.2% during the 3rd quarter. DT Investment Partners LLC now owns 380 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 150 shares in the last quarter. Values First Advisors Inc. purchased a new position in Boston Scientific during the 3rd quarter valued at about $28,000. Dakota Wealth Management grew its holdings in Boston Scientific by 14.8% during the 3rd quarter. Dakota Wealth Management now owns 57,795 shares of the medical equipment provider’s stock valued at $4,843,000 after buying an additional 7,455 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC grew its holdings in Boston Scientific by 7.4% during the 3rd quarter. Mount Yale Investment Advisors LLC now owns 16,794 shares of the medical equipment provider’s stock valued at $1,407,000 after buying an additional 1,159 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on BSX. UBS Group lifted their target price on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Canaccord Genuity Group lifted their target price on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a report on Monday, December 9th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Thursday, February 6th. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, Raymond James upped their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $107.39.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $104.44 on Friday. The company has a market cap of $154.12 billion, a price-to-earnings ratio of 83.55, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company has a 50-day moving average price of $97.98 and a 200-day moving average price of $89.38. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, equities analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 2,657 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.41, for a total value of $277,417.37. Following the completion of the transaction, the executive vice president now directly owns 24,294 shares of the company’s stock, valued at $2,536,536.54. This represents a 9.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Daniel J. Brennan sold 67,333 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the completion of the sale, the chief financial officer now owns 225,808 shares in the company, valued at approximately $23,764,033.92. This trade represents a 22.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 153,640 shares of company stock valued at $15,718,289 over the last three months. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.